TBPH Company Profile and Key Details

TBPH has shown sold momentum, gaining 3.92% over the past week and 43.2% over the past quarter, though year-to-date performance is up 9.14%. Short-term trend indicators are bearishly aligned (SMA20 -6.25%, SMA50 -5.5%, SMA200 23.07%). The stock’s 14-day RSI is 38.26 (weak momentum), while the ATR of 0.87 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -13.5% below its high and over 130.25% above its low. Average 10-day trading volume of 2.92 million shares is significantly above the 3-month average of 778.87 thousand, indicating heightened recent market interest.

Theravance Biopharma Inc generated EPS of $0.56 over the past year. Five-year average earnings growth is 22.95%. Wall Street analysts project EPS growth of 66.26% annually over the next five years. The latest quarter delivered EPS of -$0.11. The next quarter is forecast at $1.01. Next year's EPS is expected at $37.33. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 7 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $15.00. The high target offers 134.88% upside. The low target suggests -11.92% downside. The mean target is $26.58. This offers 56.08% upside. Theravance Biopharma Inc earnings surprise history is frequent misses against expectations. The quarter that ended August 10, 2026, missed forecasts by -251.72%. The prior quarter beat by -457.14%. Over the last six quarters, Apple has recorded several small beats. These include 54.55% in May 08, 2025.

Theravance Biopharma Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $11.83. This means the shares are trading above this model’s fair value.

The stock is currently mid-range between its 52-week high and low $8.12 and $21.03. With a market capitalization of about $882.64 million, Theravance Biopharma Inc is classified as a small-cap and shows lower-than-market volatility (beta ~0.17). Key stats such as the average daily volume over the past year has been around 870.81 thousand shares, trading with heavier-than-usual volume. Headquartered in South San Francisco, CA, Theravance Biopharma Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rick E. Winningham, the company employs approximately 90 people and listed since May 16, 2014. Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.

Theravance Biopharma Inc has 51.83 million shares outstanding. The public float is 24.15 million shares, elevated short interest at 13.28% of float. This equals 4.31 million shares. The short ratio is 4.62 days. Institutional investors hold 99.19% of the float. Insiders own 4.61%. Samaha Eli holds 8.01 million shares, Winningham Rick E has 1.35 million shares and GRAHAM RICHARD A has 346.84 thousand shares. Over the past six months, insider transactions show net selling. They sold 13.31 thousand shares across 2 transactions.

Theravance Biopharma Inc trades at a P/E ratio of 16.01, slightly below the S&P 500 average, with a price-to-sales ratio of 8.46 and a price-to-book ratio of 3.04 trading at moderately above to book value. The P/FCF stands at 17.03, also above market averages.

Our AI price prediction model suggests that Theravance Biopharma Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.23%, with price expected at $17.07 by October 07, 2026, within a range of $16.81 to $17.35 3-Month Outlook: Projected rise of 11.69%, reaching $19.02 by December 22, 2026, with a range of $18.80 to $19.26. 1-Year Outlook: Projected gain of 18.91%, with price at $20.25 by September 23, 2027, within a range of $19.33 to $21.00.

Theravance Biopharma Inc (NASDAQ:TBPH) shares are flat 9.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Theravance Biopharma Inc trading at a premium to the broader market with a P/E of 16.01. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $25.52, suggesting 49.85% upside. Our AI forecast model points to short-term strength (0.23% over two weeks), a medium-term rise (11.69% over three months), and a longer-term gain (18.91% over one year), with expected trading ranges indicating moderate volatility.